[{"id":"b54c377f-73ac-4c27-8f1c-a96d3052690a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03499795","created_at":"2023-07-03T22:09:19.913Z","updated_at":"2024-07-02T16:35:42.988Z","phase":"Phase 2","brief_title":"VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2","source_id_and_acronym":"NCT03499795","lead_sponsor":"Inovio Pharmaceuticals","biomarkers":" CD8 • TNFRSF9","pipe":" | ","alterations":" CD8 positive","tags":["CD8 • TNFRSF9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bizalimogene ralaplasmid (VGX-3100)"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 05/15/2018","start_date":" 05/15/2018","primary_txt":" Primary completion: 06/16/2020","primary_completion_date":" 06/16/2020","study_txt":" Completion: 05/26/2021","study_completion_date":" 05/26/2021","last_update_posted":"2023-07-14"}]